𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Excretion of tumor-associated antigen(s) in the urine of patients with colon carcinoma

✍ Scribed by Sanford J. Finck; Rishab K. Gupta; Armando E. Giuliano; Donald L. Morton

Publisher
John Wiley and Sons
Year
1982
Tongue
English
Weight
488 KB
Volume
21
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Urine samples collected from patients with colon carcinoma and from normal donors were tested for antigenic activity by the microcomplement fixation assay. When autologous serum was used as the antibody source, 65.4% (17/26) of the urine samples from patients with colon carcinoma were positive for antigen as opposed to only 10% (2/20) from normal volunteers. Absorption of a representative serum with cultured colon cancer cells completely removed reactivity against its autologous urine. Using this serum to screen urine from colon carcinoma patients, antigenic activity was found in 71.4% (30/46) of the samples; however, only 10% (2/20) of the urine samples from apparently healthy volunteers were positive. Analysis of urine samples collected from three patients before and after resection of their primary colon carcinoma and from nine patients undergoing hyperthermia for liver metastases revealed that two of the patients who had curative surgical procedures had marked decreases in urinary antigen levels by the second postoperative day, while the third patient whose disease was unresectable had no significant decrease. Seven of nine patients with metastatic disease had a greater than four fold increase in antigen activity after hyperthermia and chemotherapy. These results suggest that tumor‐associated antigens were excreted into urine, possibly the result of treatment‐caused tumor necrosis. Therefore, assessment of tumor‐associated antigen(s) in the urine of patients with colon carcinoma may serve as a marker for response to treatment of this disease.

📜 SIMILAR VOLUMES

Excretion of a tumor-associated trypsin
Excretion of a tumor-associated trypsin inhibitor (TATI) in urine of patients with gynecological malignancy
✍ Marja-Liisa Huhtala; Kari Kahanpää; Markku Seppää; Hannu Halila; Ulf-Håkan Stenm 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 French ⚖ 359 KB

## Abstract In earlier studies we reported the finding of a tumor‐associated peptide that also occurred at high concentrations in early amniotic fluid. Determination of the N‐terminal sequence of this peptide revealed that it is closely related or identical to the pancreatic secretory trypsin inhib

Immunohistochemical evidence of immune r
Immunohistochemical evidence of immune responses to tumor-associated antigens in lymph nodes of colon carcinoma patients
✍ Renato Mariani-Costantini; Raffaella Muraro; Clara Valli; Roberto Bei; Francesca 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 877 KB

The authors investigated by immunohistochemical study the drainage of three tumor-associated antigens in unaffected regional lymph nodes of colon cancer patients. The study was conducted using monoclonal antibodies (MoAb) directed against different epitopes of the tumor-associated glycoprotein, TAG-

Analysis of the prognostic significance
Analysis of the prognostic significance of cytosolic determination of CA 125 tumor-associated antigen, carcinoembryonic antigen and squamous cell carcinoma antigen in patients with nonsmall cell lung carcinoma
✍ Antonio L. Picardo; Manuel Díez; Antonio Torres; Marisa Maestro; Dolores Ortega; 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 532 KB

BACKGROUND. The use of new prognostic factors as guidelines for the indication of treatment ancillary to surgery has been advocated for patients with nonsmall cell lung carcinoma (NSCLC). This article is an analysis of the prognostic information derived from determination of tumor-tissue cytosolic c

Specific active immunotherapy in patient
Specific active immunotherapy in patients with adenocarcinoma of the colon utilizing tumor-associated antigens (TAA). A phase I clinical trial
✍ Ariel Hollinshead; E. George Elias; Myron Arlen; Barbara Buda; Maria Mosley; Jos 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 838 KB

Twenty-two patients received specific active immunotherapy (TAA vaccine once per month for 3 months), with the duration of follow-up, as of July 1984, ranging from 3 months to 36 months (median, 21 months). Of these, seven had Dukes Bz, seven had Dukes C, and eight had Dukes D lesions. All received